GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

GW Pharmaceuticals plc announced that the European Commission (EC) has approved the marketing authorisation… The post GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy appeared first on Daily Marijuana Observer.

READ MORE BELOW
Source : MJ OBSERVER
Link to original : GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy
reposted by Cannabis News World